

**CHILDREN'S ORGAN
TRANSPLANT ASSOCIATION, INC.**

FINANCIAL STATEMENTS

June 30, 2024 and 2023

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.

Bloomington, Indiana

FINANCIAL STATEMENTS

June 30, 2024 and 2023

CONTENTS

INDEPENDENT AUDITOR'S REPORT	1
FINANCIAL STATEMENTS	
STATEMENTS OF FINANCIAL POSITION	3
STATEMENTS OF ACTIVITIES	4
STATEMENTS OF FUNCTIONAL EXPENSES	5
STATEMENTS OF CASH FLOWS	7
NOTES TO FINANCIAL STATEMENTS	8

INDEPENDENT AUDITOR'S REPORT

The Board of Directors
Children's Organ Transplant Association, Inc.
Bloomington, Indiana

Opinion

We have audited the financial statements of Children's Organ Transplant Association, Inc. (COTA), which comprise the statements of financial position as of June 30, 2024 and 2023, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of COTA as of June 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of COTA and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about COTA's ability to continue as a going concern for one year from the date the financial statements are available to be issued.

(Continued)

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of COTA's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about COTA's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.


Crowe LLP

Indianapolis, Indiana
August 23, 2024

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
 STATEMENTS OF FINANCIAL POSITION
 June 30, 2024 and 2023

	<u>2024</u>	<u>2023</u>
ASSETS		
Cash and cash equivalents	\$ 125,420	\$ 342,010
Interest receivable	335,000	326,000
Pledges and grants receivable (Note 2)	434,415	525,890
Prepays and other assets	83,336	60,294
Investments (Note 6)	42,854,053	40,467,479
Property and equipment, net (Note 5)	<u>498,270</u>	<u>496,428</u>
	<u>\$ 44,330,494</u>	<u>\$ 42,218,101</u>
LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable and accrued expenses	\$ 139,243	\$ 151,593
Deferred revenue	76,946	71,317
Line of credit payable (Note 7)	86,462	-
Note payable	<u>18,099</u>	<u>24,775</u>
	320,750	247,685
Net assets		
Without donor restrictions	(518,862)	(1,573,469)
Without donor restrictions, board designated	<u>2,513,052</u>	<u>2,513,052</u>
Total without donor restrictions	1,994,190	939,583
With donor restrictions	<u>42,015,554</u>	<u>41,030,833</u>
	<u>44,009,744</u>	<u>41,970,416</u>
	<u>\$ 44,330,494</u>	<u>\$ 42,218,101</u>

See accompanying notes to financial statements.

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
STATEMENTS OF ACTIVITIES
Years ended June 30, 2024 and 2023

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
REVENUE						
Contributions and grants	\$ 935,478	\$ 5,056,763	\$ 5,992,241	\$ 1,367,735	\$ 5,391,515	\$ 6,759,250
In-kind contributions	26,413	-	26,413	-	-	-
Other fundraising income	216,265	-	216,265	198,592	-	198,592
Interest and dividend income (net of investment expenses of \$167,298 and \$154,965, respectively)	1,883,606	7,721	1,891,327	1,741,318	9,216	1,750,534
Realized and unrealized gain (loss) on investments	977,544	145,205	1,122,749	(120,088)	97,809	(22,279)
Lease income and other	124,970	-	124,970	126,821	-	126,821
Releases from restrictions	<u>4,224,968</u>	<u>(4,224,968)</u>	<u>-</u>	<u>3,862,318</u>	<u>(3,862,318)</u>	<u>-</u>
Total revenue	8,389,244	984,721	9,373,965	7,176,696	1,636,222	8,812,918
EXPENSES						
Patient campaign program	5,779,467	-	5,779,467	5,252,322	-	5,252,322
Management and general	916,255	-	916,255	807,467	-	807,467
Fundraising	638,915	-	638,915	578,570	-	578,570
Total expenses	<u>7,334,637</u>	<u>-</u>	<u>7,334,637</u>	<u>6,638,359</u>	<u>-</u>	<u>6,638,359</u>
Changes in net assets	1,054,607	984,721	2,039,328	538,337	1,636,222	2,174,559
Net assets, beginning of year	<u>939,583</u>	<u>41,030,833</u>	<u>41,970,416</u>	<u>401,246</u>	<u>39,394,611</u>	<u>39,795,857</u>
Net assets, end of year	<u>\$ 1,994,190</u>	<u>\$ 42,015,554</u>	<u>\$ 44,009,744</u>	<u>\$ 939,583</u>	<u>\$ 41,030,833</u>	<u>\$ 41,970,416</u>

See accompanying notes to financial statements.

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
Year ended June 30, 2024 (with summary totals for the year ended June 30, 2023)

	<u>Patient Campaign</u>	<u>Management and General</u>	<u>Fundraising</u>	<u>2024 Total</u>	<u>2023 Total</u>
Salaries and wages	\$ 954,038	\$ 432,221	\$ 326,865	\$ 1,713,124	\$ 1,565,811
Payroll taxes	65,627	30,415	22,371	118,413	108,936
Employee benefits	206,235	96,223	71,823	374,281	361,595
Professional services and fees	71,556	177,970	54,537	304,063	226,985
Transplant patient-related expenses	4,224,968	-	-	4,224,968	3,862,318
Travel	67,679	29,830	32,004	129,513	115,427
Certification fees	10,446	-	-	10,446	20,372
Advertising	58,756	456	30,189	89,401	84,140
Utilities	5,214	2,363	1,801	9,378	8,075
Insurance	14,572	6,607	5,071	26,250	25,431
Repairs and maintenance	2,908	35,491	1,157	39,556	22,888
Depreciation	34,126	15,462	11,717	61,305	47,938
Contracted services	-	41,412	-	41,412	48,092
In-kind expenses	26,413	-	-	26,413	-
Supplies and office equipment	21,507	24,461	473	46,441	27,946
Postage	8,743	4,300	4,427	17,470	22,354
Telephone	6,583	7,301	1,592	15,476	16,683
Miscellaneous	96	11,743	74,888	86,727	73,368
	<u>\$ 5,779,467</u>	<u>\$ 916,255</u>	<u>\$ 638,915</u>	<u>\$ 7,334,637</u>	<u>\$ 6,638,359</u>

See accompanying notes to financial statements.

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
Year ended June 30, 2023

	<u>Patient Campaign</u>	<u>Management and General</u>	<u>Fundraising</u>	<u>2023 Total</u>
Salaries and wages	\$ 861,196	\$ 391,453	\$ 313,162	\$ 1,565,811
Payroll taxes	59,739	27,474	21,723	108,936
Employee benefits	197,722	91,974	71,899	361,595
Professional services and fees	39,813	149,489	37,683	226,985
Transplant patient-related expenses	3,862,318	-	-	3,862,318
Travel	69,340	23,363	22,724	115,427
Certification fees	20,372	-	-	20,372
Advertising	60,948	2,363	20,829	84,140
Utilities	4,441	2,019	1,615	8,075
Insurance	13,987	6,358	5,086	25,431
Repairs and maintenance	10,085	9,136	3,667	22,888
Depreciation	26,366	11,984	9,588	47,938
Contracted services	-	48,092	-	48,092
Supplies and office equipment	5,090	22,294	562	27,946
Postage	12,249	4,143	5,962	22,354
Telephone	8,512	6,094	2,077	16,683
Miscellaneous	144	11,231	61,993	73,368
	<u>\$ 5,252,322</u>	<u>\$ 807,467</u>	<u>\$ 578,570</u>	<u>\$ 6,638,359</u>

See accompanying notes to financial statements.

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
STATEMENTS OF CASH FLOWS
Years ended June 30, 2024 and 2023

	<u>2024</u>	<u>2023</u>
Cash flows from operating activities		
Changes in net assets	\$ 2,039,328	\$ 2,174,559
Adjustments to reconcile changes in net assets to net cash from operating activities:		
Depreciation	61,305	47,938
Realized and unrealized (gains) losses on investments	(1,122,749)	22,279
Contributions restricted for long term investment	(109,875)	(4,800)
Change in assets and liabilities:		
Interest receivable	(9,000)	(23,000)
Pledges and grants receivable	91,475	(525,890)
Prepays and other assets	(23,042)	22,708
Accounts payable and accrued expenses	(12,350)	(47,736)
Deferred revenue	<u>5,629</u>	<u>(800)</u>
Net cash from operating activities	920,721	1,665,258
Cash flows from investing activities		
Purchase of property and equipment	(63,147)	(158,674)
Proceeds from sale of investments	6,599,010	4,660,394
Purchase of investments	<u>(7,862,835)</u>	<u>(5,927,008)</u>
Net cash from investing activities	(1,326,972)	(1,425,288)
Cash flows from financing activities		
Proceeds from contributions restricted for long term investment	109,875	4,800
Payments on note payable	(6,676)	(6,616)
Proceeds from line of credit	371,350	237,237
Payments on line of credit	<u>(284,888)</u>	<u>(259,512)</u>
Net cash from financing activities	189,661	(24,091)
Net change in cash and cash equivalents	(216,590)	215,879
Cash and cash equivalents at beginning of year	<u>342,010</u>	<u>126,131</u>
Cash and cash equivalents at end of year	<u>\$ 125,420</u>	<u>\$ 342,010</u>
Supplemental disclosure of cash flow information		
Interest paid	\$ 2,930	\$ 2,694
Supplemental disclosure of non-cash transactions		
In-kind contributions	\$ 26,413	\$ -

See accompanying notes to financial statements.

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization: Children's Organ Transplant Association, Inc. (COTA) was incorporated as a not-for-profit organization in 1986 under the laws of the State of Indiana. Throughout the United States, COTA helps families with children and young adults in need of life-saving transplants by providing fundraising assistance and family support. COTA also educates the public regarding the need for organ and tissue donations.

COTA is made up of a Board of Directors and a dedicated staff. The Board sets the direction of COTA, makes policies, and reviews the status of the organization on a regular basis. The staff implements the direction and policy set by the Board and runs the day-to-day operations of COTA. Staff duties include the management of the national headquarters; the organization and development of new campaigns; continuing support of existing campaigns; financial accounting and reporting for community campaigns; the training and support of volunteer corps; promotions and public relations of COTA; and the development of national fundraising programs to run the organization.

Basis of Presentation: The financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (GAAP).

Income Taxes: COTA is exempt from income taxes on income from related activities under Section 501(c)(3) of the U.S. Internal Revenue Code and corresponding state tax law. Accordingly, no provision has been made for federal or state income taxes. Additionally, COTA has been determined not to be a private foundation under Section 509(a) of the Internal Revenue Code.

COTA is subject to income taxes on income generated from activities that are unrelated to its exempt purpose. COTA did not pay any unrelated business income taxes for the years ended June 30, 2024 and 2023.

Financial Accounting Standards Board (FASB) guidance states that a tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the "more likely than not" test, no tax benefit will be recorded.

COTA does not expect the total amount of unrecorded tax benefits to significantly change in the next 12 months. COTA recognizes interest and/or penalties related to income tax matters in income tax expense. COTA did not have any amounts accrued for interest and penalties at June 30, 2024 and 2023.

Functional Allocation of Expenses: The costs of providing various programs and other activities have been summarized on a functional basis in the statements of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited, based on the actual direct expenditures and cost allocations based upon estimates by COTA, which includes time allocation.

Use of Estimates in Preparation of Financial Statements: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents: Cash and cash equivalents consist of bank deposits in accounts that are federally insured up to \$250,000 per financial institution. Additionally, for purposes of the statement of cash flows, COTA considers all highly liquid investments purchased with an original maturity 12 of months or less to be cash equivalents. From time to time COTA's cash balances exceed federally insured limits.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Investments: Investments are recorded at fair value based on estimates made by the investment trust administrators using quoted market prices or the market prices of similar securities. Unit investment trusts and alternative investments, such as limited partnerships, are valued based upon net asset values (NAV) as reported by the investment manager or other unobservable inputs, as independent market valuations are not available. COTA believes the carrying amount of these financial instruments is a reasonable estimate of fair value. Alternative investments are not readily marketable, and their estimated value is subject to uncertainty. Therefore, there may be a material difference between their estimated value and the value that would have been used had a readily determinable fair value for such investments existed.

Investments are initially recorded at cost if they were purchased or at their fair value on the date of the gift if they were received as a donation. Unrealized gains and losses on investments are included in the statements of activities.

COTA's Board of Directors has approved an investment policy statement with which the Board intends to preserve investment capital and meet the cash flow needs of the organization.

Pledges and Grants Receivable: Pledges and grants receivable represent the remaining balance of unconditional promises to give that have not yet been paid. Pledges and grants that are expected to be collected within one year or less are recorded at net realizable value. Pledges and grants that are expected to be collected beyond one year are recorded at the present value of their estimated future cash flows. The pledges and grants have been discounted using a risk-weighted interest rate applicable during the time the pledge was made. Changes in the pledge and grant discounts are recognized as contribution revenue each year until the pledge is paid in full. Conditional promises to give are recognized only when the conditions on which they depend are substantially met and the promises become unconditional.

Allowance for Uncollectible Pledges and Grants: The allowance for uncollectible pledges and grants is determined by management based upon COTA's historical losses, specific circumstances and general economic conditions. Periodically, management reviews receivables and records an allowance based on current circumstances, and charges off the receivable against the allowance when all attempts to collect the receivable are deemed to have failed in accordance with COTA's collection policy. An allowance for uncollectible pledges and grants was not deemed necessary by management as of June 30, 2024 and 2023.

Property and Equipment: Property and equipment are stated at cost or, if donated to COTA, at fair value on the date of acquisition. Additions and improvements are capitalized; expenditures for routine maintenance are charged to operations. Depreciation is provided over the estimated useful lives of the various classes of assets on the straight-line method. COTA has a capitalization policy that states that all property and equipment in excess of \$1,000 are to be capitalized and depreciated. The estimated useful lives are as follows:

	<u>Years</u>
Building and improvements	10-40
Office furniture and equipment	3-10

Impairment of Long-Lived Assets: On an ongoing basis, COTA reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amounts may be overstated. COTA recognizes impairment losses if the undiscounted cash flows expected to be generated by the asset are less than the carrying value of the related asset. The impairment loss adjusts the assets to fair value. As of June 30, 2024 and 2023, management believes that no impairments existed.

Net Assets Without Donor Restrictions: Net assets without donor restrictions represents contributions by donors and other revenues and all related expenses that the Board of Directors has discretionary control to use in carrying on the operations of COTA.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Net Assets Without Donor Restrictions, Board Designated: The Board of Directors has designated certain net assets without donor restrictions as the "Vernon B. Smith Memorial Fund." These funds are to be used at the discretion of the Board of Directors.

Net Assets With Donor Restrictions: Net assets with donor restrictions are those net assets whose use has been limited by donors to later periods or for specified purposes. Net assets with donor restrictions of a temporary nature are restricted by donor-imposed requirements that the funds be used for transplant-related expenses for patients served by COTA. COTA also has 67 accounts with donor restrictions of a temporary nature that require that the funds be used for transplant and transplant-related expenses for patients who reside within specific geographic areas or for patients who suffer from specific illnesses. Net assets are released from restrictions when used for the satisfaction of program restrictions. Net assets with donor restrictions to be kept in perpetuity are those net assets for which the donor has stipulated that the contribution be maintained in perpetuity as an endowment to support future operations and program activities. Donor-imposed restrictions limiting the use of assets or their economic benefit neither expire with the passage of time nor can be removed by satisfying a specific purpose.

Revenue Recognition: In accordance with GAAP, revenues are recognized when earned. All contributions and grants are considered available for unrestricted use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as support with donor restrictions. If a restriction is fulfilled in the same time period in which the contribution is received, the contribution is reported as with donor restrictions of a temporary nature and released from restrictions.

In-Kind Contributions and Donated Services: In addition to receiving cash contributions, COTA on occasion receives in-kind contributions from various donors. It is the policy of COTA to record the estimated fair value of certain in-kind contributions as both revenue and expense for the programs or activities benefited. For the years ended June 30, 2024 and 2023, COTA received \$26,413 and \$0 of in-kind contributions, respectively.

Additionally, contributions of services are recognized if the services received create or enhance nonfinancial assets or require specialized skills, that are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. For the years ended June 30, 2024 and 2023, there were no donated services.

Advertising: Advertising costs are expensed during the period in which the advertising first took place.

Subsequent Events: Management has performed an analysis of the activities and transactions subsequent to June 30, 2024 to determine the need for any adjustments or disclosures within the financial statements for the year ended June 30, 2024. Management has performed their analysis through August 23, 2024, the date the financial statements were available to be issued.

NOTE 2 - PLEDGES AND GRANTS RECEIVABLE

Pledges and grants receivable at June 30, 2024 and 2023 are unconditional promises to give from various donors. In February 2023, COTA received a grant for \$756,000, restricted for transplant related expenses for patients in the state of Texas. The grant was receivable in scheduled installments over three years and has an outstanding balance of \$264,000 and \$516,000 at June 30, 2024 and 2023, respectively.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 2 - PLEDGES AND GRANTS RECEIVABLE (Continued)

The following is the detail of the pledges and grants receivable balances at June 30, 2024 and 2023:

	<u>2024</u>	<u>2023</u>
Amounts receivable in:		
Less than one year	\$ 434,415	\$ 261,890
One to five years	<u>-</u>	<u>264,000</u>
Total pledges and grants receivable	<u>\$ 434,415</u>	<u>\$ 525,890</u>

NOTE 3 - PATIENT ACCOUNTS

A patient relationship is initiated by a family requesting assistance from COTA to help organize a fundraising campaign. The family signs a contract (patient agreement) which gives COTA the right to raise funds on behalf of the patient and use the patient's picture and story as promotional material. COTA works with community volunteers to organize a campaign to raise funds to cover the costs of transplant and related costs.

At the start of the campaign, a volunteer designated by the family coordinates community fundraising efforts and sends proceeds to the COTA corporate office. In addition, some donors send contributions directly to COTA's office. The funds are recorded as contributions with donor restrictions in COTA's accounting system when deposited.

Contributions received from donors with a restriction that they be used for patient transplant related expenses are allocated to specific patient accounts according to set procedures approved and reviewed by COTA's Allocation Committee, a standing committee of the Board of Directors, three times each year. The allocations are based upon the estimated cost of the transplant that is needed by the patient. As transplant-related expenses are incurred by the patients, the funds are released from restriction.

As patients are treated, transplant-related expenses will be reviewed for payment by COTA. If a patient passes away and after all transplant-related expenses are considered, the money remaining is also reallocated to a pool that is available for meeting approved expenses of other patient accounts. In addition to transplant expenses, these funds also pay for patient websites, merchant fees, and general emergency grants for patients. For the years ended June 30, 2024 and 2023, transplanted-related expenses were \$4,224,968 and \$3,862,318, respectively. The COTA staff and Allocations reviews the funding needs of patients regularly and allocates funds to patient accounts as the needs arise. On an annual basis the needs of past patients are reviewed for possible allocations. For the years ended June 30, 2024 and 2023, reallocations from the pool of funds from deceased patients were \$415,914 and \$191,537, respectively.

In addition to community fundraising campaigns, COTA regularly solicits and receives gifts from individuals, corporate donors, membership organizations, and grants from foundations. These gifts vary in restrictions for transplant related expenses to specific states, diagnoses, specific organs, or other donor-requested restrictions.

Though COTA is dedicated to ensuring that no child is excluded from a life-saving transplant because of a lack of funds, COTA is not legally required by contract to cover all transplant-related expenses. When COTA provides additional funding to a patient's campaign, COTA may utilize funds from the patient reallocation fund and the Vernon B. Smith Memorial Fund at its discretion.

At June 30, 2024 and 2023, COTA had 2,823 and 2,828 active patient accounts, representing \$41,527,477 and \$40,652,631 of net assets with donor restrictions of a temporary nature. For the years ended June 30, 2024 and 2023, COTA had contributions with donor restrictions for transplant-related expenses of \$5,056,763 and \$5,391,515, respectively.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 4 - PATIENT COMMITMENTS AND GUARANTEES

Some health care providers may require a commitment from COTA to cover the transplant expense for an individual so that the hospital is assured that it will be paid for its services. After COTA has made a commitment to a health care provider for an individual patient, they continue to work with the community volunteers to raise money to cover the commitment made by COTA and other costs. As of June 30, 2024 and 2023, no significant patient commitments are outstanding.

When the transplant has taken place, but the community volunteers has not raised enough money to cover COTA's commitment, then COTA records a contribution expense and guarantee liability on the statement of financial position. As of June 30, 2024 and 2023, no guarantee liabilities are outstanding.

NOTE 5 - PROPERTY AND EQUIPMENT

COTA's property and equipment are as follows at June 30:

	<u>2024</u>	<u>2023</u>
Land	\$ 80,645	\$ 80,645
Buildings and improvements	895,483	895,483
Office furniture and equipment	<u>585,628</u>	<u>522,481</u>
	1,561,756	1,498,609
Accumulated depreciation	<u>(1,063,486)</u>	<u>(1,002,181)</u>
	<u>\$ 498,270</u>	<u>\$ 496,428</u>

NOTE 6 - INVESTMENTS

COTA's investments at fair value consist of the following at June 30:

	<u>2024</u>	<u>2023</u>
Money market funds	\$ 498,447	\$ 666,998
Municipal bonds	2,408,997	1,796,648
Corporate bonds	24,888,866	24,937,941
U.S. treasury securities	816,963	441,378
Exchange traded funds	4,798,570	3,611,952
Mutual funds	438,593	623,902
Equities	4,363,864	3,783,037
Preferred equities	2,220,682	2,239,709
Asset-backed securities	111,868	132,674
Unit investment trusts	2,197,207	2,116,112
Limited partnerships	<u>109,996</u>	<u>117,128</u>
	<u>\$ 42,854,053</u>	<u>\$ 40,467,479</u>

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 6 - INVESTMENTS (Continued)

Investment return is comprised of the following at June 30:

	<u>2024</u>	<u>2023</u>
Interest and dividend income, net of investment expenses of \$167,298 and \$154,965 for 2024 and 2023, respectively	\$ 1,891,327	\$ 1,750,534
Realized gains on sale of investments	\$ 690,380	\$ 319,784
Unrealized gains (losses) on investments	<u>432,369</u>	<u>(342,063)</u>
Realized and unrealized gains (losses) on investments	<u>\$ 1,122,749</u>	<u>\$ (22,279)</u>

The various investments in bonds, exchange traded funds, mutual funds, equities and other investments are exposed to a variety of uncertainties, including interest rate, market, and credit risks. Due to the level of risk associated with certain investments, it is possible that changes in the values of these investments could occur in the near term. Such changes could materially affect the amounts reported in COTA's financial statements.

NOTE 7 - LINE OF CREDIT

COTA has an unsecured line of credit at a local bank which provides for borrowings of up to \$500,000. Interest is charged on amounts borrowed at a rate of 8.5% and 8.25% at June 30, 2024 and 2023, respectively. The line of credit expired on December 28, 2023 and was renewed through December 28, 2024. There was an outstanding balance of \$86,462 and \$0 at June 30, 2024 and 2023, respectively. Interest expense was \$2,930 and \$2,694 for the years ended June 30, 2024 and 2023, respectively.

NOTE 8 - EMPLOYEE BENEFITS

For the years ended June 30, 2024 and 2023, COTA sponsored two defined contribution retirement plans. Contributions to both plans are made for all employees with at least one year of service. The first plan requires mandatory employer contributions of 7% of each eligible employee's total compensation. Contributions under the second plan are a matching contribution by COTA. Each eligible employee may contribute up to the IRS limits of his or her salary and COTA will match 4% of their contribution. Considering both defined contribution plans, the maximum amount contributed by COTA cannot exceed 11% of each eligible employee's compensation. Employee benefit expense under these plans was \$138,602 and \$140,702 for the years ending June 30, 2024 and 2023, respectively.

NOTE 9 - OPERATING LEASE AS LESSOR

COTA has entered into a lease agreement as the lessor of a portion of their headquarters building beginning September 13, 2013, through September 12, 2023. On September 13, 2023, COTA extended the term of the lease for three years, terminating on September 30, 2026. The lessee has the option to extend the term for two additional terms of three years each. The cost of insurance, taxes, and maintenance are paid by the lessee. Other expenses related to the lease are included in COTA's general and administrative expense.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 9 - OPERATING LEASE AS LESSOR (Continued)

Total minimum rentals to be collected under the operating lease with noncancelable lease terms as of June 30, 2024 over future fiscal years are:

2025	\$ 126,773
2026	131,843
2027	<u>33,281</u>
	<u>\$ 291,897</u>

NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS

GAAP defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in COTA's principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

GAAP establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect a reporting entity's own assumptions about the assumptions that market participants would use in pricing an asset or liability.

In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.

The fair values of equities, mutual funds, money market funds, exchange traded funds, and certain unit investment trusts are based on quoted prices on nationally recognized securities exchanges. (Level 1 inputs)

The fair value of corporate and municipal bonds, U.S. treasury securities, preferred equities, and asset-backed securities are based on inputs that are observable, but not active using the market approach. These inputs include matrix pricing models and comparison to prices of similar assets. (Level 2 inputs)

The fair value of some unit investment trusts and alternative investments, such as limited partnerships, are based upon the NAV or its equivalent using the market method, as reported by the investment manager, with additional analysis performed by management, as such investments have significant unobservable valuation inputs and are excluded from the valuations hierarchy. Due to current market conditions as well as limited trading activity of these securities, the fair value of the securities is highly sensitive to assumption changes and market volatility. The market approach is used to determine fair value.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)

COTA's investments in closed unit investment trusts are held as part of their larger portfolio of investments and the investment strategy of the underlying investments vary. The trusts have termination dates ranging through August 2025, however, there are no liquidation restrictions and the investments can be liquidated on a daily basis.

COTA held an investment in one limited partnership as of June 30, 2024 and 2023, which is classified as an energy royalty contract partnership.

- Energy royalties is comprised of one limited partnership whose strategy is to purchase energy related royalty rights contracts (primarily oil and gas). No liquidation date has been set for this limited partnership; however, management has estimated that it will be liquidated in 10 to 15 years.

Currently there are no unfunded commitments to the one limited partnership in which COTA is invested.

The following table summarizes COTA's investments that are measured at fair value on a recurring basis as of June 30, 2024 and 2023:

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
<u>2024</u>				
Money market funds	\$ 498,447	\$ -	\$ -	\$ 498,447
Municipal bonds	-	2,408,997	-	2,408,997
Corporate bonds	-	24,888,866	-	24,888,866
U.S. treasury securities	-	816,963	-	816,963
Exchange traded funds	4,798,570	-	-	4,798,570
Mutual funds:				
Fixed income	162,698	-	-	162,698
Equity	127,094	-	-	127,094
REITs	148,801	-	-	148,801
Equities:				
Large cap	4,363,864	-	-	4,363,864
Preferred equities	-	2,220,682	-	2,220,682
Asset-backed securities	-	111,868	-	111,868
Unit investment trusts	<u>1,122,483</u>	<u>-</u>	<u>-</u>	<u>1,122,483</u>
	<u>\$ 11,221,957</u>	<u>\$ 30,447,376</u>	<u>\$ -</u>	41,669,333
Investments valued at NAV:				
Closed unit investment trusts				1,074,724
Limited partnerships:				
Energy royalties				<u>109,996</u>
				<u>\$ 42,854,053</u>

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
<u>2023</u>				
Money market funds	\$ 666,998	\$ -	\$ -	\$ 666,998
Municipal bonds	-	1,796,648	-	1,796,648
Corporate bonds	-	24,937,941	-	24,937,941
U.S. treasury securities	-	441,378	-	441,378
Exchange traded funds	3,611,952	-	-	3,611,652
Mutual funds:				
Fixed income	254,254	-	-	254,254
Equity	172,645	-	-	172,645
REITs	197,003	-	-	197,003
Equities:				
Large cap	3,783,037	-	-	3,783,037
Preferred equities	-	2,239,709	-	2,239,709
Asset-backed securities	-	132,674	-	132,674
Unit investment trusts	<u>1,092,497</u>	<u>-</u>	<u>-</u>	<u>1,092,497</u>
	<u>\$ 9,778,386</u>	<u>\$ 29,548,350</u>	<u>\$ -</u>	39,326,736
Investments valued at NAV:				
Closed unit investment trusts				1,023,615
Limited partnerships:				
Energy royalties				<u>117,128</u>
				<u>\$ 40,467,479</u>

NOTE 11 - ENDOWMENT COMPOSITION

COTA's endowment consists of donor-restricted funds for operational or patient-related needs.

Interpretation of Relevant Law: The Board of Directors of COTA have interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA), as adopted in the State of Indiana, as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result, COTA classifies as net assets with donor restrictions to be kept in perpetuity the original value of gifts donated to the permanent endowment. The remaining portion of the donor-restricted endowment fund that is not classified in net assets with donor restrictions to be kept in perpetuity is classified as net assets with donor restrictions of a temporary nature until those amounts are appropriated for expenditure by the organization in a manner consistent with the standard of prudence prescribed by UPMIFA.

In accordance with UPMIFA, the Board of Directors considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of COTA and the donor-restricted endowment fund
- (3) General economic conditions and the possible effect of inflation and deflation
- (4) The expected total return from income and the appreciation of investments
- (5) The investment policies of COTA and other resources of COTA

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 11 - ENDOWMENT COMPOSITION (Continued)

Endowment net asset composition by type of fund as of June 30, 2024:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Endowment funds	\$ -	\$ 1,027,686	\$ 1,027,686

Endowment net asset composition by type of fund as of June 30, 2023:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Endowment funds	\$ -	\$ 764,885	\$ 764,885

Changes in endowment net assets for year ended June 30, 2024:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Net assets, beginning of year	\$ -	\$ 764,885	\$ 764,885
Investment income, net of fees	-	7,721	7,721
Net realized and unrealized gains	-	145,205	145,205
Investment gain, net	-	152,926	152,926
Contributions	-	109,875	109,875
Net assets, end of year	\$ -	\$ 1,027,686	\$ 1,027,686

Changes in endowment net assets for year ended June 30, 2023:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Net assets, beginning of year	\$ -	\$ 653,060	\$ 653,060
Investment income, net of fees	-	9,216	9,216
Net realized and unrealized gains	-	97,809	97,809
Investment gain, net	-	107,025	107,025
Contributions	-	4,800	4,800
Net assets, end of year	\$ -	\$ 764,885	\$ 764,885

Return Objectives and Risk Parameters: COTA has adopted investment and spending policies for endowment assets that attempt to preserve and enhance the purchasing and earning value of the funds being invested, seek competitive investment performance, produce annual income, and produce growth to hedge inflation over time. COTA expects its endowment funds, over time, to provide an average rate of return of at least 5% plus CPI. Actual returns in any given year may vary from this amount.

(Continued)

CHILDREN'S ORGAN TRANSPLANT ASSOCIATION, INC.
NOTES TO FINANCIAL STATEMENTS
June 30, 2024 and 2023

NOTE 11 - ENDOWMENT COMPOSITION (Continued)

Strategies Employed for Achieving Objectives: To satisfy its objectives, COTA relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). COTA targets a diversified asset allocation of fixed income, U.S. equities, real estate, and international equities to achieve its long-term return objectives within prudent risk constraints.

Spending Policy and How the Investment Objectives Relate to Spending Policy: COTA has a policy of appropriating for distribution each year up to 5% of the endowment fund's average fair value of the three fiscal year ends preceding the fiscal year in which the distribution is planned. If the fair value of the assets falls below the principal, no amounts will be appropriated unless approved by the Board. This is consistent with COTA's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return. Endowment fund principal, unless otherwise directed by the donor, shall not be expended.

NOTE 12 - LIQUIDITY AND AVAILABILITY

COTA's financial assets available within one year of the statement of financial position date for general expenditure are as follows:

	<u>2024</u>	<u>2023</u>
Financial assets at year-end:		
Cash and cash equivalents	\$ 125,420	\$ 342,010
Interest receivable	335,000	326,000
Pledges and grants receivable (less than one year)	434,415	261,890
Investments	<u>42,854,053</u>	<u>40,467,479</u>
Total financial assets	43,748,888	41,397,379
Less amounts not available for general expenditure within one year:		
Board designated net assets	(2,513,052)	(2,513,052)
Donor restricted funds	<u>(37,703,054)</u>	<u>(36,566,833)</u>
	<u>(40,216,106)</u>	<u>(39,079,885)</u>
Financial assets available to meet general expenditures within one year	<u>\$ 3,532,782</u>	<u>\$ 2,317,494</u>

As part of COTA's liquidity management, COTA invests its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Management only considers the amount budgeted from donor restricted funds for the next year to be available for general operations. For the years ending June 30, 2024 and 2023, COTA budgeted \$4,312,500 and \$4,200,000 of donor restricted funds, respectively, to be available for transplant patient-related expenses as part of the general operations in the next year. COTA has board designated net assets of \$2,513,052 at June 30, 2024 and 2023. While these funds could be made available for general expenditures within the next year, the amount would first be subject to approval by the board.

In addition, COTA has an unsecured line of credit at a local bank which provides for borrowings of up to \$500,000. Available credit balances at June 30, 2024 and 2023 were \$413,538 and \$500,000, respectively.